Taipei, Taiwan, 29 December 2025 — Lotus Pharmaceuticals (1795:TT; “Lotus” or “the Company”), a multinational pharmaceutical company, today announce its sponsor for the Street Medicine Program operated by the Charitable Service Association (臺灣思安慈善服務協會), with funding supporting the program across 2025–2026.
The Street Medicine Program delivers regular medical consultations, follow-up care, and health education through professional medical teams to individuals experiencing homelessness, economic hardship, unemployment, chronic illness, and mental health challenges, who often gather around major train stations around Taiwan. By providing medical services directly on the streets, the program aims to expand access to healthcare for these disadvantaged individuals.
Since its launch in 2022, the Street Medicine Program has served more than 1,500 patient visits, providing monthly outreach clinics, medication support, referrals, and coordinated social services. Lotus is honoured to be part of the program during 2025–2026, with a total of 75 street-based medical services planned around major train stations in Taipei, New Taipei, Taoyuan, and Taichung.
This reflects Lotus’ long-standing commitment to expanding access to medicines and healthcare services, particularly for underserved populations. Through the sponsorship, Lotus supports the program’s delivery of stable, long-term street-based medical services that integrate healthcare with social support, helping individuals in need to stabilise their health, reconnect with essential public services, and move towards independent and sustainable living, while reducing preventable disease progression and avoidable medical emergencies.
Petar Vazharov, Chief Executive Officer of Lotus Pharmaceuticals, commented: “At Lotus, expanding access to healthcare is our core priority. We are pleased to work with the Charitable Service Association through the Street Medicine Program to support such meaningful initiatives that help bring essential healthcare services to those most in need, while contributing to efforts to narrow resource gaps and support health equity. “
About Lotus
Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercialising both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness
Media Inquiries:
Yihsuan Kuo, Investor Relations Assistant Manager
Jeffrey Tsang, Head of Investor Relations and Corporate Communications
+886 2 2700 5908
investor@lotuspharm.com